-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Article source: Medical Rubik's Cube Info
Author: Shi Bei
On September 20, AVEO Oncology announced that the FDA granted the company a fast track designation for the targeting HGF monoclonal antibody ficlatuzumab for the treatment of patients with recurrent or recurrent head and neck squamous cell carcinoma (R/R HNSCC)
Ficlatuzumab (AV-299) is a potent hepatocyte growth factor (HGF) immunoglobulin G1 (IgG1) inhibitory antibody under investigation, which can bind to HGF ligands with high affinity and specificity
In June 2021, the company announced the use of ficlatuzumab as a single agent or combined with EGFR monoclonal antibody cetuximab for relapsed or refractory metastatic head and neck squamous cells that had previously received immunotherapy, chemotherapy, and cetuximab.
Positive results were obtained in the Ficlatuzumab combined with cetuximab group.
Ficlatuzumab combined with cetuximab is well tolerated and has similar expected toxicity to HGF/cMet inhibitors.